Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Glaxosmithkline (GSK) Share Price

Price 1,806.50p on 26-01-2026 at 11:42:28
Change 5.50p 0.31%
Buy 1,807.00p
Sell 1,806.00p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Unknown 0.00 at 1,807.00p
Day's Volume: 471,901
Last Close: 1,801.00p
Open: 1,802.50p
ISIN: GB00BN7SWP63
Day's Range 1,795.00p - 1,808.00p
52wk Range: 1,242.50p - 1,909.50p
Market Capitalisation: £72.88b
VWAP: 1,802.91704p
Shares in Issue: 4.03b

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Higher Yield, FTSE 350 ex Investment Trusts, FTSE 350 , FTSE 100,

Glaxosmithkline (GSK) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 0 1,807.00p SI Trade
 11:42:28 - 26-Jan-26
Sell* 134 1,806.50p Automatic Execution
 11:42:28 - 26-Jan-26
Sell* 60 1,806.50p Automatic Execution
 11:42:28 - 26-Jan-26
Sell* 39 1,806.50p Automatic Execution
 11:42:28 - 26-Jan-26
Sell* 41 1,806.50p Automatic Execution
 11:42:28 - 26-Jan-26
Unknown* 0 1,807.00p SI Trade
 11:42:06 - 26-Jan-26
Buy* 2 1,807.00p SI Trade
 11:41:18 - 26-Jan-26
Unknown* 0 1,807.50p SI Trade
 11:41:15 - 26-Jan-26
Unknown* 0 1,806.50p SI Trade
 11:41:15 - 26-Jan-26
Unknown* 0 1,807.50p SI Trade
 11:41:15 - 26-Jan-26
See more Glaxosmithkline trades

Glaxosmithkline (GSK) Share Price History

Time period:
to
Date Open High Low Close Volume
26th Jan 2026 (Mon) 1,802.50 1,808.00 1,795.00 1,801.00 471,901
23rd Jan 2026 (Fri) 1,814.00 1,814.00 1,796.00 1,801.00 9,062,710
22nd Jan 2026 (Thu) 1,792.50 1,808.00 1,776.50 1,804.50 4,820,384
21st Jan 2026 (Wed) 1,786.50 1,798.50 1,777.00 1,787.50 6,414,843
20th Jan 2026 (Tue) 1,802.00 1,805.50 1,774.00 1,795.50 7,498,672
19th Jan 2026 (Mon) 1,800.00 1,816.00 1,793.00 1,816.00 5,056,429
16th Jan 2026 (Fri) 1,838.00 1,845.00 1,795.50 1,816.50 14,632,764
15th Jan 2026 (Thu) 1,890.50 1,895.50 1,845.00 1,848.00 4,980,454
14th Jan 2026 (Wed) 1,856.50 1,880.50 1,853.50 1,880.50 6,552,424
13th Jan 2026 (Tue) 1,868.50 1,874.00 1,833.00 1,858.00 5,789,190
12th Jan 2026 (Mon) 1,879.50 1,902.00 1,866.00 1,877.00 5,647,857
9th Jan 2026 (Fri) 1,875.00 1,896.00 1,871.00 1,886.00 6,348,596
8th Jan 2026 (Thu) 1,891.50 1,908.50 1,880.00 1,891.00 6,026,419
7th Jan 2026 (Wed) 1,902.00 1,909.50 1,869.50 1,901.50 7,532,634
6th Jan 2026 (Tue) 1,818.00 1,905.50 1,817.50 1,899.50 11,458,875
5th Jan 2026 (Mon) 1,846.00 1,847.00 1,800.00 1,820.50 5,344,789
2nd Jan 2026 (Fri) 1,828.00 1,849.00 1,821.00 1,831.50 5,188,093
1st Jan 2026 (Thu) 1,824.50 1,824.50 1,824.50 1,824.50 0
31st Dec 2025 (Wed) 1,833.50 1,835.00 1,824.50 1,824.50 2,468,218
30th Dec 2025 (Tue) 1,815.00 1,835.00 1,812.50 1,830.50 3,231,417
29th Dec 2025 (Mon) 1,815.50 1,823.50 1,810.50 1,823.00 3,647,051
26th Dec 2025 (Fri) 1,805.50 1,805.50 1,805.50 1,805.50 0
See more Glaxosmithkline price history

Glaxosmithkline (GSK) Regulatory News

Date Source Headline
20th Jan 2026 7:05 am RNS GSK to acquire RAPT Therapeutics
20th Jan 2026 7:00 am RNS Agreement on changes to ViiV minority shareholding
16th Jan 2026 3:30 pm RNS Director/PDMR Shareholding
15th Jan 2026 3:30 pm RNS Director/PDMR Shareholding
13th Jan 2026 3:30 pm RNS Director/PDMR Shareholding
7th Jan 2026 7:05 am RNS EC approval of Shingrix PFS
7th Jan 2026 7:00 am RNS Positive phase 3 data for GSK's bepirovirsen
6th Jan 2026 7:00 am RNS Exdensur approved in Japan
5th Jan 2026 3:30 pm RNS Director/PDMR Shareholding
5th Jan 2026 3:00 pm RNS Total Voting Rights
See more Glaxosmithkline regulatory news

Glaxosmithkline (GSK) Share News

GSK's RSV treatment, Arexvy, secures approval for wider use in EU

26th Jan 2026 08:27

(Alliance News) - GSK PLC on Monday said the European Commission has approved an expanded indication for its respiratory syncytial virus vaccine Arexvy, allowing use in all adults aged 18 and over. Read More

LONDON BRIEFING: GSK wins EU nod for RSV shot; Spire in early talks

26th Jan 2026 07:59

(Alliance News) - GSK wins EU approval to expand use of its RSV vaccine Arexvy to all adults over 18, while Grainger unveils plans for a 195-home West London development, and Impax Environmental Markets outlines its tender offer plan amid continued pressure from activist investor Saba. Read More

IN BRIEF: GSK drug approved in China to treat uncontrolled asthma

23rd Jan 2026 10:11

GSK PLC - London-based pharmaceuticals company - Says China's National Medical Products Administration has approved Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, or FF/UMEC/VI) in a new indication, for adults with uncontrolled asthma. This adds to the therapy's current licence for use in chronic obstructive pulmonary disease, and makes it the first and only single inhaler triple therapy approved for the maintenance treatment of both respiratory conditions in China. GSK says approval was based on its Captain study, "which showed that in patients uncontrolled on inhaled corticosteroids/long-acting beta agonist (ICS/LABA), the additional bronchodilation provided by FF/UMEC/VI demonstrated significant improvements in lung function compared with FF/VI." Says asthma is one of the most prevalent chronic respiratory diseases in China, with around 46 million adults affected and approximately half of patients experiencing uncontrolled symptoms. Read More

IN BRIEF: RTW Biotech welcomes GSK deal to buy RAPT Therapeutics

21st Jan 2026 11:37

RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Notes GSK PLC's announcement on Tuesday that it has agreed to acquire RAPT Therapeutics Inc. Says RAPT, a Californian biopharmaceutical company developing therapies for inflammatory and immunologic diseases, represented 0.15% of its net asset value as of December 31. The all-cash transaction values RAPT at USD2.2 billion, with shareholders to receive USD58 per share. RTW says the price represents a 65% premium to RAPT's closing price on Monday. Read More

LONDON MARKET OPEN: FTSE 100 sinks further as tariff fears grow

20th Jan 2026 09:13

(Alliance News) - Stock prices in London slid further on Tuesday morning for the second day, as tariff threats from the US continued to unsettle investors. Read More

See more Glaxosmithkline news
FTSE 100 Latest
Value10,151.06
Change7.62

Login to your account

Forgot Password?

Not Registered